Interleukin-6 as a Biomarker for Rheumatoid Arthritis-Associated Interstitial Lung Disease: A Retrospective Study.

Zhiping Yu, Ji Liu, Letian Chen, Ming Jiang

Abstract read

In one paragraph

Article in International journal of general medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it

0cells of the map it votes in

1citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

Inflammatory activity as a predictor of clinical deterioration in interstitial pneumonia with autoimmune features: a comparative cohort study with connective tissue disease-associated interstitial lung disease.Therapeutic advances in respiratory disease
Article

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Zhiping Yu *Department of Respiratory and Critical Care Medicine, Yingtan People's Hospital, Yingtan, Jiangxi, People's Republic of China.

Ji Liu *Department of Hematology, Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, People's Republic of China.

Letian ChenDepartment of Respiratory and Critical Care Medicine, Yingtan People's Hospital, Yingtan, Jiangxi, People's Republic of China.

Ming JiangDepartment of Respiratory and Critical Care Medicine, Yingtan People's Hospital, Yingtan, Jiangxi, People's Republic of China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: This study aims to assess the predictive value of interleukin-6 (IL-6) as a biomarker in patients with rheumatoid arthritis-associated interstitial lung disease (RA-ILD). Methods: A total of 361 RA patients (236 RA non-ILD and 125 RA-ILD patients) are included in the study, and stratified analysis is performed according to age and gender. The RA-ILD group is divided into mild ILD, moderate ILD, and severe ILD groups based on HRCT score. Using logistic regression analysis to investigate the risk association between IL-6 and rheumatoid arthritis-associated interstitial lung disease (RA-ILD), and employing receiver operating characteristic (ROC) to determine the value of IL-6 for distinguishing RA-ILD. Pearson's analysis and linear regression are used to analyze the association between IL-6 and RA disease activity, High-Resolution Computed Tomography (HRCT) scores, and Krebs Von den Lungen-6 (KL-6). Results: The level of IL-6 in the RA-ILD group is higher than that in the RA non-ILD group ( Conclusion: IL-6 may be used as a new peripheral blood biomarker to predict RA-ILD.

Indexed as

biomarkercytokineIL-6inflammationRA-ILD

Identifiers

PMID41859315

DOI10.2147/IJGM.S567633

PMCPMC12998923

What OpenQuestion holds

Textmetadata

LicenceCC BY-NC

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.